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ABSTRACT Resistance to artemisinin-based combination therapy (ACT) in the Plas-
modium falciparum parasite is threatening to reverse recent gains in reducing global
deaths from malaria. While resistance manifests as delayed parasite clearance in pa-
tients, the phenotype can only spread geographically via the sexual stages and mos-
quito transmission. In addition to their asexual killing properties, artemisinin and its
derivatives sterilize sexual male gametocytes. Whether resistant parasites overcome
this sterilizing effect has not, however, been fully tested. Here, we analyzed P. falcip-
arum clinical isolates from the Greater Mekong Subregion, each demonstrating de-
layed clinical clearance and known resistance-associated polymorphisms in the
Kelch13 (PfK13var) gene. As well as demonstrating reduced asexual sensitivity to
drug, certain PfK13var isolates demonstrated a marked reduction in sensitivity to ar-
temisinin in an in vitro male gamete formation assay. Importantly, this same reduc-
tion in sensitivity was observed when the most resistant isolate was tested directly
in mosquito feeds. These results indicate that, under artemisinin drug pressure,
while sensitive parasites are blocked, resistant parasites continue transmission. This
selective advantage for resistance transmission could favor acquisition of additional
host-specificity or polymorphisms affecting partner drug sensitivity in mixed infec-
tions. Favored resistance transmission under ACT coverage could have profound im-
plications for the spread of multidrug-resistant malaria beyond Southeast Asia.
KEYWORDS Anopheles stephensi, Kelch13, Plasmodium falciparum, artemisinin
combination therapies (ACTs), gametocytes, multidrug-resistant malaria, transmission
blocking
Malaria kills more than 400,000 people each year (1). While there has been amarked reduction in global rates of malaria disease since the new millennium,
progress has stalled and recently even reversed in some regions (1). A critical factor
threatening future gains in malaria control is the emergence and spread of drug
resistance in the most virulent parasite Plasmodium falciparum (2). Of most concern is
the reported spread of resistance to frontline artemisinin-based drugs in the Greater
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Mekong Subregion (GMS) of Southeast Asia (SEA) (3–5). Artemisinin has revolutionised
treatment for severe malaria. The drug acts rapidly to clear the clinical symptoms of
malaria by killing the asexual parasite in host red blood cells (RBCs). Although a precise
mechanism of action is contested, it is thought that intracellular iron-mediated activa-
tion of artemisinin arising from parasite metabolism of hemoglobin causes the drug to
be both highly reactive and consumed rapidly in the process of its action (6). Conse-
quently, use of artemisinin or its derivatives requires coformulation with longer-lasting
partner drugs as artemisinin-based combination therapies (ACTs). In recent years,
however, resistance to both artemisinin and partner drugs, including piperaquine and
mefloquine, has increased in prevalence throughout SEA (4, 7–10). The spread of such
multidrug resistant parasites beyond the GMS could prove catastrophic for global
malaria control (11, 12).
Resistance to artemisinin is strongly associated with nonsynonymous single nucle-
otide polymorphisms (SNPs) in the propeller domain of P. falciparum Kelch13 (PfK13)
(13) a protein with a role in hemoglobin endocytosis from the host cell (14, 15). Based
on SNP analysis, several PfK13 variants (PfK13var) have been defined displaying different
degrees of delayed parasite clearance in patients under ACT treatment. PfK13var include
mutually exclusive SNPs giving rise to amino acid changes C580Y, R539T, I543T and
Y493H (4, 8, 16, 17). While the precise mechanism by which different PfK13var determine
resistance remains ill-defined (6), PfK13var parasites show an upregulation in the
unfolded protein response (18). In asexual ring stages, the presence of PfK13C580Y
results in the reduced endocytotic uptake of hemoglobin, potentially leading to
reduced intracellular activity of artemisinin (14, 15). Persistence of parasites in the blood
of infected individuals will lead to their delayed clearance and ultimately treatment
failure. Among PfK13 polymorphisms, the PfK13C580Y genotype is the most widely
spread variant currently circulating in SEA (7, 8).
Drug resistance and its spread are traditionally seen through the prism of disease, which,
in the case of malaria, is the asexual replicative stages of the life cycle carried in blood
circulation. However, resistance can only spread with passage of the parasite through the
mosquito, a fundamental step in the Plasmodium life cycle (19). Transmission of malaria
parasites is solely mediated by nonpathogenic sexual stages called gametocytes. These
gametocytes mature over the course of 10 to 12 days and are the only stages infectious to
mosquitoes (19). During a mosquito blood feed, male and female gametocytes are taken up
and activated in the mosquito midgut into male and female gametes. These activated
gametes then fertilize and form a motile zygote (ookinete) that infects the midgut epithe-
lium, forming an oocyst on the gut lining (20). The oocyst eventually bursts releasing
sporozoites that can be transmitted back into humans during a subsequent bite from an
infected mosquito.
While the activity of artemisinin derivatives on asexual stage parasites is well known, one
overlooked property of these drugs is their ability to target sexual stages, specifically their
ability to block the activation of male gametes (exflagellation), which underpins transmis-
sion (21, 22). This raises the question as to whether artemisinin-resistant parasites are also
resistant to this sterilizing effect in the context of transmission to the mosquito. Here, we
sought to test how clinical isolates with demonstrated tolerance or treatment delay against
artemisinin (i.e., asexual stage growth) fair in their transmissibility through the mosquito
under artemisinin coverage. We showed that male gametocytes of a PfK13C580Y isolate are
activated under drug pressure and are thus able to infect mosquitoes under artemisinin
treatment compared to a sensitive control. These findings have important implications for
modeling the spread of resistance across geographical regions. This additional effect of
artemisinin resistance on transmission emphasizes the need for future combination ther-
apies that include a transmission-blocking component if we are to stem the spread of
resistance beyond the GMS.
RESULTS
Selection and adaptation of Southeast Asian P. falciparum clinical isolates for
in vitro study. P. falciparum clinical isolates that successfully adapted to long-term
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culture (Chotivanich, unpublished data) were derived from a previous, multicenter,
open-label, randomized trial collecting samples from patients with acute, uncompli-
cated malaria (16). All isolates were sequenced and assessed for multiplicity of infection
(MOI) at point-of-care and determined to be sufficiently homozygous to make cloning
(and potentially loss of ability to form gametocytes) unnecessary (23). Among isolates,
five were followed further based on their ability to form functional mature gametocytes
in vitro. These were compared to the standard laboratory control parasite strain NF54.
Each was validated by PCR, confirming the five clinical isolates have variant polymor-
phisms in PfK13 (Table 1). Each P. falciparum isolate was tested ex vivo for sensitivity to
the artemisinin derivative artesunate using the 24-h trophozoite maturation inhibition
assay (TMI). The TMI assesses the effect of artemisinin derivatives on the maturation of
asexual ring stages to trophozoites in comparison to an artemisinin-sensitive control
(24). While PfK13var isolates presented a wide range of TMI 50% inhibitory concentra-
tion (IC50) values, they all showed increased resistance to artesunate compared to a
PfK13WT culture-adapted Thai and non-gametocyte-producing laboratory strain, TM267
(Table 1).
In addition to the PfK13 genotype, the genetic background of each parasite isolate
was investigated to explore whether additional mutations might be present, such as
those associated with other drug resistance phenotypes. Whole-genome sequencing
analysis was completed for each, confirming different PfK13 genotypes (Table 2). In
addition, multiple previously reported mutations in genes associated with various drug
sensitivities were found among PfK13var isolates (as reviewed in reference 2) (Table 2).
Mutations were found in the chloroquine resistance transporter (pfcrt), agreeing with
reported mutations found in some parasites following ACT treatment (25). None of the
isolates, however, carried mutations in pfcrt associated with increased DHA-piperaquine
treatment failure (7, 8, 26) or piperaquine resistance in vitro (27, 28). In addition, all
isolates carried mutations in four genes that are associated with the PfK13C580Y
haplotype, namely, fd (ferredoxin), arps10 (apicoplast ribosomal protein S10), mdr2
(multidrug resistance protein 2), and crt (chloroquine resistance transporter) (Table 2)
(17).
Increased copy numbers for the multidrug resistance transporter pfmdr1 and en-
zymes plasmepsin II/plasmepsin III are known to be associated with enhanced survival
of parasites exposed to mefloquine or piperaquine, respectively (29–32). To test if any
of the field isolates harbored copy number variations, we created sashimi plots of the
next-generation sequencing coverage (Fig. S1 in the supplemental material) and found
that plasmepsin II/plasmepsin III are duplicated for isolate APL4G (Table 2). APS3G and
APL5G both had copy number variants of pfmdr1 (Table 2). This suggests that APS3G
and APL5G will also likely show resistance to mefloquine, while APL4G might also show
resistance to piperaquine (30, 33).
Variation in PfK13 results in a growth defect in asexual blood stages but not
in mosquito stages. PfK13var that are associated with artemisinin resistance are known
to also show reduced asexual blood-stage growth (34, 35). To validate this in selected









TM267 1995 Thailand ND 1.82 (1.3–2.3)b WT (24)
ARN1G May 2011–April 2013 Ranong, Thailand 7.1 17.69 (0.26) G449A
APS2G May 2011–April 2013 Srisaket, Thailand 6.1 24.19 (4.16) R539T
APS3G May 2011–April 2013 Srisaket, Thailand 6.2 33.56 (1.04) R539T
APL4G May 2011–April 2013 Pailin, West Cambodia 5.1 17.17 (2.6) C580Y
APL5G May 2011–April 2013 Pailin, West Cambodia 7.7 13.53 (6.24) C580Y
aND, not done.
bIC50 values of field isolates assayed with three independent biological replicates using the trophozoite maturation inhibition assay (TMI) (24). Standard deviations are
indicated in brackets (SD). The P. falciparum TM267 assay control isolate originates from a previous study (24) with others from (16). For the wild-type strain TM257,
the parentheses contain the 95% confidence interval.
cAs determined by PCR.
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isolates, parasites were set up in synchronized ring-stage cultures, at a starting para-
sitemia of 2%, and followed over the course of 8 days. Parasitemia was analyzed every
second day by flow cytometry and cultures rediluted to 2%. NF54 parasites showed a
cumulative parasitemia as expected under standard laboratory conditions (Figure 1a).
Parasites with a PfK13var showed a significantly reduced replication rate in in vitro
compared to NF54 (Figure 1a), agreeing with previous studies (34, 35). To explore the
underlying mechanism of slowed growth, we measured the number of merozoites per
schizont, which will directly determine potential growth rates (36). Late synchronized
schizonts were blocked from merozoite egress using the protein-kinase G (PKG) inhib-
itor, compound 2 (37). Thin smears, 12 h later, were then made of each culture and
stained with the nuclear stain 4=,6-diamidino-2-phenylindole (DAPI) to count nuclei per
schizont. PfK13var isolates displayed fewer nuclei per schizont than the NF54 control,
suggesting that the observed reduced growth rate may at least be partially explained
by a reduction in the number of progeny (Figure 1b).





ARN1G APS2G APS3G APL5G APL4G
PF3D7_1343700 Kelch protein K13 G449A x    
R539T  x x  
C580Y    x x
PF3D7_0112200 Multidrug resistance-associated protein 1 H191Y x X x x x
K202E    x 
N325S     
S437A x X x x x
I876V x   x x
F1390I x   x x
PF3D7_0417200 Bifunctional dihydrofolate reductase-thymidylate
synthase
N51I x x x x x
C59R x x x x x
S108N x x x x x
I164L     x
PF3D7_0523000 Multidrug resistance protein 1 Y184F  x x x x
amplification    x 
PF3D7_0709000 Chloroquine resistance transporter K76T x x x x x
T93Sa     
H97Y     
F145I     
I218F     
Q271E x x x x x
M343I     
G353V     
I356Tb x x x x x
R371I x x x x x
PF3D7_0810800 Hydroxy-methyldihydropterin pyrophosphokinase-
dihydropteroate synthase (PPPK-DHPS)
S436A  x x  
K540E x x x  
K540N    x x
A581G x   x x
PF3D7_1303500 Sodium/hydrogen exchanger N894K x    
V950G x x x x x
H1375Y x  x  
H1379Y  x  x 
F1557S x x x x x
PF3D7_140800
PF3D7_1408100
Plasmepsin II/plasmepsin III amplification     x
PF3D7_1318100 Ferredoxin, putative D193Yb x x x x x
PF3D7_1460900 Apicoplast ribosomal protein S10 precursor,
putative (arps10)
V127Mb  x x x x
D128H x x x x x
PF3D7_1447900 Multidrug resistance protein 2 (heavy metal
transport family) (MDR2)
S208N x x x x x
G299D x x x x x
F423Y x x x x x
T484Ib x  x x x
aAll amino acid changes in italics have recently been associated with ACT treatment failure within the eastern GMS.
bAmino acid changes highlighted with boldface have previously showed strong associations with artemisinin resistance (17).
cThe presence (x) or absence () of the polymorphism is indicated for each protein.
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To investigate the transmission capability of each P. falciparum field isolate, we
induced gametocytes at a starting parasitemia of 2% (38) and, 14 days post induction,
fed cultures to Anopheles stephensi mosquitoes by standard membrane feeding assay
(SMFA) (39). No significant differences were noted in the stage V (mature) gametocy-
taemia between different isolates. NF54 showed higher overall stage V gametocytaemia
compared to Pf13var (Figure S2a). Male gametocyte exflagellation rates (exflagellation/
l of culture) showed some variability between isolates. Although all the isolates were
seeded at equal hematocrit and asexual parasitemia percentages, we cannot directly
compare those rates (Figure S2a). Rather, they indicate male gametocyte viability of
each individual culture before SMFAs (Figure S2b and c). At 10 days postfeeding,
mosquito midguts were dissected and oocyst numbers recorded. All field isolates were
found to be capable of infecting mosquito midguts at varied intensity levels, i.e., oocyst
counts per midgut, as reported previously for Cambodian field isolates (40). To test if
PfK13var led to a reduced replication rate in mosquito stage growth (following the
reduced merozoite count), we measured the diameter of each oocyst in these infections
as a proxy for replication. Oocyst size showed no consistent pattern of variation
compared to NF54, other than a PfK13R539T isolate, which displayed significantly larger
oocysts (Figure S2c). This shows that while variations in PfK13 may reduce parasite
multiplication rate in the asexual blood stage, they do not appear to directly influence
transmission and growth in the mosquito stage.
Exflagellation sensitivity to different antimalarials among isolates with varied
PfK13 genotypes. It has previously been shown that artemisinin and its derivatives
FIG 1 Characterization of P. falciparum clinical isolates. (a) Relative cumulative growth of P. falciparum
clinical isolates compared to NF54. Parasitemia was measured by flow cytometry every other day for
eight consecutive days (four replication cycles). Six biological replicates from two parallel experiments
are shown. Clinical isolates with K13var grow significantly slower than NF54 (K13WT, unpaired t test, **,
P  0.01; ***, P  0.0001). Error bars denote standard deviation (SD). (b) K13var parasites have less nuclei
per schizont than NF54 parasites with the exception of isolate ARN1G (unpaired t test, **, P  0.01; ***,
P  0.0001). Dark pink bars indicate the median and light pink bars denote the interquartile range.
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have an inhibitory effect on male gametocyte exflagellation, sterilizing male gameto-
cytes from activation, but have no effect on female gametocyte activation (21, 22). To
explore whether PfK13var isolates were resistant to this sterilizing effect, we applied a
modified dual gamete formation assay (PfDGFA) (22) measuring only the male gamete
activation, i.e., male gamete formation assay (MGFA) for this purpose. A 24-h incubation
of cultures with the artemisinin derivative DHA was found to be insufficient to elicit a
complete inhibition of exflagellation for NF54 parasites (Fig. S3), likely as a result of the
instability of the drug, which has been shown to have an in vitro half-life of 2.3 h in
human plasma at pH 7.4 and 37°C (41). To improve activity and allow for a comparative
analysis between isolates, gametocytes were exposed to a second compound dose at
24 h after the first, resulting in a double-dose regimen with a readout after 48 h. Double
exposure consistently gave complete inhibition of male activation with DHA at the
highest concentration tested (Fig. S3). In parallel, two other artemisinin derivatives and
four other antimalarial drugs were tested by the MGFA (Fig. S4 and S5). Exflagellation
rates for PfK13var isolates varied in the presence of drug, with the two PfK13R539T and
PfK13C580Y isolates consistently showing tolerance to artemisinin derivatives (Fig. 2) but
not to other compounds, i.e., UCT048 and NITD609. These two pipeline antimalarials are
known to target PfPI4K (42) and PfATP4 (43), respectively. The lack of a consistent
pattern of reduced sensitivity to artemisinin-based drugs across PfK13var isolates sug-
gests that K13 polymorphisms alone likely do not completely explain sensitivity of
sexual stages to artemisinin treatment. This observation is corroborated by similar
findings with piperaquine resistance, which is mostly, but not always, associated with
copy number variants in plasmepsin II/plasmepsin III (30), but has now been associated
with specific pfcrt mutations in vitro (27, 28). In addition, the two isolates exhibiting
reduced exflagellation sensitivity to artemisinin-based drugs, namely, APS3G and
APS5G, are the only two isolates in our study exhibiting amplification of pfmdr1 (Fig.
S1). This is especially interesting as a reduction in copy number variations of pfmdr1
were previously found to increase DHA sensitivity in asexual parasites (44, 45). However,
the presence of even a single isolate with reduced sensitivity to artemisinin-based
drugs in both asexual and sexual stages suggests there is the potential that a resistant
strain might be favored for transmission to the mosquito.
To mimic the impact of DHA’s short elimination half-life (46) on its exflagellation
effect, NF54 stage III (early) and stage V (mature) gametocytes were incubated with a
single DHA concentration, and the drug replaced with half of the concentration every
50 min (range 3.5 M to 0.027 M DHA, a total of eight incubations equaling 6.67 h). A
50-min exposure time was selected as a trade-off between the fast elimination half-life
of DHA and the minimum time required for gametocytes to settle by gravity under the
assay conditions. DHA was then washed out and gametocytes matured until control
FIG 2 Exflagellation inhibition reported as IC50 values of clinical isolates. Two parasite isolates (APS3G and APL5G) show consistent resistance to
sterilizing effects of three different artemisinin-related drugs, dihydroartemisinin (DHA) (a) artemether (b) and artemisone (c) on exflagellation
compared to the NF54 PfK13WT control. One additional isolate (APLS2G) showed increased resistance to artemisone. IC50 values were compared
to NF54 (unpaired t test, *, P  0.05; **, P  0.01). Open circles denote each biological replicate. Error bars denote the standard error of the mean
(SEM).
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cultures reached stage V or an additional 48 h, respectively. When mature stage V
gametocytes were exposed to rapidly reduced DHA concentrations, exflagellation was
still effectively inhibited (54.72%). Exflagellation of early-stage gametocytes was almost
entirely inhibited (Figure 3a and c). This is likely explained through a killing effect, as
gametocytes disappear from the culture when early stages are exposed to DHA (Figure
3b and d). Interestingly, the sterilizing effect of DHA on stage V gametocytes appeared
to be irreversible, as it was sustained even after the drug had been washed out and was
independent from an immediately visible reduction in gametocytaemia (Figure 3d).
Transmission of field isolates with different PfK13 genotypes under DHA drug
selection. To explore the hypothesis that PfK13var-associated resistance might allow
resistant parasites to efficiently infect mosquitoes under drug coverage, we selected
the PfK13C580Y isolate APL5G. This isolate showed a comparable level of mosquito
FIG 3 Inhibition of exflagellation is irreversible and independent of a reduction in gametocytaemia for stage V gametocytes. (a and c) Effect of DHA in vitro
simulated half-life on gametocytaemia and male gametogenesis. (a) Nonpurified stage III (culture day 9) and stage V (culture day 14) gametocytes were exposed
to gametocyte culture medium (GCT) containing 3.5 M DHA or DMSO and culture supernatants were replaced every 50 min with aliquots containing half the
DHA concentration of the previous exposure (range 3.5 M to 0.027 M). Cultures were then washed stringently and continued until DMSO control cultures
reached stage V gametocyte maturity (stage III), or for an additional 48 h (stage V). (c) Exflagellation was assessed and quantified to DMSO controls. (b and d)
Irreversible effect of DHA on stage V male gametocytes. (b) Nonpurified stage III, IV, and V (culture days 9, 11, and 14) gametocytes were each exposed to 1.6 M
DHA for 24 h. Cultures were washed vigorously and continued until DMSO control cultures reached stage V gametocyte maturity (stage III and V) or for an
additional 24 h (stage V). (d) Exflagellation levels were measured and normalized to DMSO controls (left y axis). Gametocytaemia was counted per 1,000 RBC
and quantified to DMSO control (right y axis). Inhibition of exflagellation was irreversible and independent of a reduction in gametocytaemia for stage V
gametocytes. Diamonds and triangles denote the means of biological repeats and error bars denote SEM.
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infection to NF54 (Fig. S2) and also showed a high level of male gamete activation
resistance to DHA (Fig. 2). Gametocyte cultures of both parasites, APL5G and NF54,
were exposed to a range of DHA concentrations for 48 h using our double-dosing
regimen, before feeding to A. stephensi mosquitoes by SMFA. The DHA concentration
range was selected to ensure exflagellation IC50s for both lines were incorporated in the
SMFA three-point dose-response. At day 10 postfeeding, mosquitos were dissected and
midguts examined for oocyst load (Fig. S6). Generalized linear mixed effects models
were used to analyze infection intensity (number of oocysts per midgut) and infection
prevalence (proportion of midguts with oocysts) in response to treatment with DHA, in
order to incorporate data from 18 individual SMFA experiments within the same
modeling framework. A decrease in both intensity and prevalence of infected mosqui-
toes was observed for both parasite isolates with increasing DHA concentration (Figure
4a and b). A significant decrease in both the oocyst intensity (ratio of oocyst
counts  0.73, 95% confidence interval [CI]: 0.66 to 0.80) and prevalence (odds ra-
tio  0.46, 95% CI: 0.41 to 0.52) of mosquito infection was observed for NF54 with
increasing drug concentration. In contrast, APL5G parasites (Pf13C580Y) showed no
evidence for a significant decrease in oocyst intensity with increasing DHA (ratio of oocyst
counts  0.84, 95% CI: 0.65 to 1.07). Increasing concentrations of DHA did still reduce the
FIG 4 The impact of DHA on the PfK13WT and PfK13C580Y transmission potential. Graphs show the overall results
of oocyst counts from 18 individual SMFA experiments measuring oocyst infection intensity (a) and infection
prevalence (b) of the sensitive isolate PfK13WT (NF54) versus the artemisinin-resistant PfK13C580Y isolate (APL5G)
after incubation with either DMSO (no DHA) or DHA at the specified concentrations. Points and whiskers on each
plot show the mean and the bootstrapped 95% CI for each replicate, with the predicted relationship and 95% CI
shown with the trend line and shaded region. In the absence of DHA (DMSO), APL5G was predicted to produce
significantly fewer oocysts and infections, whereas in the presence of DHA concentrations greater than 2 M DHA,
the transmission potential of PfK13C580Y was comparable to NF54/PfK13WT. (c) Fitness costs associated with DHA
resistance. The relative reduction in infection prevalence due to DHA treatment in NF54 was greater (62.7%) than
in APL5G (41.4%), which suggests that APL5G is significantly more likely to infect mosquitoes under drug treatment
(P  0.05) compared to the absence of drug.
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oocyst prevalence for APL5G (odds ratio  0.72, 95% CI: 0.56 to 0.96); however, this effect
was significantly less than the effect seen for WT parasites (Table 3).
To position these findings in the context of likely transmission events, we further
explored the impact of DHA on transmission at a single and conservatively selected
concentration of DHA (2 M) (46) in comparison with dimethyl sulfoxide (DMSO). The
peak of DHA serum concentration following the recommended WHO ACT oral dosing
regimen for artesunate exhibits a wide range with the maximum drug concentration
(Cmax) up to 7.5 M (46). Since DHA sterilizes male gametocytes irreversibly, the
presence of even a transient spike of 2 M in serum will, therefore, lead to transmission
blocking. In the absence of DHA, NF54 parasites were consistently observed to have a
higher infection prevalence (55.1%, 95% CI: 50.5% to 57.8%) compared to APL5G
parasites (19.2%, 95% CI: 13.3% to 26.0%) (Figure 4c). This suggests that a fitness cost
is associated with the APL5G genotype, which causes a sizeable reduction in the
onward probability of infection relative to wild-type (WT) parasites in the absence of
DHA in A. stephensi mosquitoes. However, this changed significantly in the presence of
DHA. At a concentration of 2 M DHA, no significant difference was observed between
NF54 parasites (20.6%, 95% CI: 27.7% to 14.3%) and APL5G parasites (12.1%, 95% CI:
4.1% to 25.4%) (Figure 4c). The equivalence of infection demonstrates a profound
impact of DHA on NF54 but not APL5G transmission, meaning that under clinically
relevant artemisinin concentrations, APL5G gametocytes are less affected than NF54
gametocytes for successful onward transmission. This observed transmission-resistance
phenotype may offset any fitness costs (such as growth) observed in the absence of
drug.
DISCUSSION
The threat of spreading artemisinin resistance for the treatment of malaria has
focused global attention on the mechanisms underlying resistance in the parasite
Plasmodium falciparum. However, only limited focus has been placed on how resistant
parasites transmit through the Anopheles mosquito vector. In this paper, we have
shown clear evidence that a clinical isolate with defined artemisinin resistance, based
on the known PfKelch13 marker (in terms of clinical delayed clearance and reduced
asexual growth sensitivity in the presence of artemisinin-based drugs), is also equally
able to transmit to mosquitoes under drug coverage.
In comparison, the wild-type pathogen strain NF54 was shown to be significantly
less likely to infect mosquitoes under drug coverage. This suggests that the use of
artemisinin will increase the probability of artemisinin resistance being transmitted due
to the significant reduction in the probability of wild-type parasites being transmitted.
The molecular basis of this transmission-resistance phenotype is likely complex and is
clearly not defined simplistically by PfK13 alone. However, the disconnect between
PfK13 and transmission resistance is clear from the observation that of the five
clinically resistant isolates tested, while each showed clear resistance to artemisinin-
based drugs in asexual growth, there was varied sensitivity in transmission stages.
However, the transmission-resistance phenotype was nonetheless robust for certain
TABLE 3 Effects of DHA concentration on oocyst prevalence and intensitya
Isolate and treatment
Prevalence of infectionb Oocyst intensityb
Odds ratio 95% CI P Ratio of oocyst counts 95% CI P
K13var in the absence of DHA 0.20 0.16–0.25 <0.001 0.17 0.13–0.23 <0.001
DHA (M): WT line 0.46 0.41–0.52 <0.001 0.73 0.66–0.80 <0.001
DHA (M): K13var 0.72 0.56–0.96 <0.001 0.84 0.65–1.07 0.069
aAnalysis was done using generalized linear mixed effects models to incorporate 18 SMFA experiments into a single analysis. Prevalence of infection (presence of at
least one oocyst) was modeled using a logistic regression (binomial error structure), with the reference being the artemisinin sensitive NF54 parasites (WT lines) in
the absence of DHA. The estimate of 0.46 (0.41 to 0.52) for the impact of DHA on the WT line indicates that for a 1 M increase in DHA, the odds of a mosquito
being infected by a WT parasite are 46%. Oocyst intensity (the number of oocysts) was modeled using a zero-inflated negative binomial distribution. Ratio of oocyst
counts refers to the change in the absolute number of oocysts relative to the control, which is the WT line in the absence of DHA. The estimate of 0.17 (0.13 to 0.23)
for K13var in the absence of DHA indicates that the expected oocyst numbers for the K13var are 17% compared to the WT.
bCI, confidence interval. Boldface P values indicate significance.
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isolates. We initially aimed to compare artemisinin-resistant parasites with locally
matched artemisinin-sensitive isolates to allow a more accurate adjustment for the
genetic background of the SEA lineages. Unfortunately, at the time of this study,
none of the wild-type isolates were producing sufficiently viable male gametocytes
and culture adaption of those lines is currently ongoing. Therefore, the canonical
NF54 strain, which has been broadly employed in transmission studies, was chosen
as the artemisinin-sensitive control.
As with previous studies, we first started with investigation of the asexual growth
rate, confirming a consistent reduced rate in resistant isolates. The asexual growth rate
reduction seen in PfK13var isolates likely acts as both a selective cost for parasite growth
(in being outcompeted in normal infections) but also likely explains how these parasites
persist during drug treatment, i.e., explaining delayed clearance (14, 15). Switching our
focus to sexual commitment and development, we next explored gametocyte produc-
tion. With the caveat that different parasite isolates always show marked differences in
gametocyte formation capacity, we did not observe any obvious reduced capacity
among PfK13var isolates in gametocyte production. All five field isolates produced
comparable numbers of mature gametocytes (stage V gametocytes) after day 14 upon
induction. Indeed, a positive correlation between drug resistance and sexual commit-
ment has been consistently reported. Patients with delayed parasite clearance due to
artemisinin resistance display higher gametocytaemia levels, suggesting an elevated
potential for transmission of these parasite isolates (16). While commitment of game-
tocytes to either male or female is poorly understood, it is entirely conceivable that
gametocytes mature or differentiate into either male or female at differing rates in each
isolate. Unfortunately, sex ratios were untested here due to a paucity of markers for
male and female gametocytes and challenges with definitive differentiation of the
sexes using Giemsa stain. Irrespective of this, gametocyte conversion rates have been
shown to be sensitive to asexual stage replication, which itself is affected by drugs. This
suggests there is the potential for a trade-off between asexual stages and sexual stages
in ensuring the spread of the artemisinin-resistant parasites (47).
With sexual commitment and exflagellation in vitro seemingly uncompromised in
resistant isolates, we next sought to explore transmissibility directly. While we saw
differences in infection intensities between the different isolates, the transmission
replication rate (as measured by oocyst size) among the five parasite field isolates and
NF54 was similar. The latter point is noteworthy, since it is clear that artemisinin-
resistant parasite isolates show a lower asexual growth rate and merozoite (progeny)
rate (Fig. 1), however, sporogony in the mosquito does not appear to be affected. Thus,
PfK13var parasites appear able to commit to sexual reproduction, activate, and transmit
to mosquitoes at similar levels as NF54 (i.e., beyond variability usually seen between
isolates). Still, it is important to note that further studies are needed to fully address the
influence of K13 genotype on oocyst growth and, ultimately, number of viable and
infectious sporozoites.
Shifting our attention to transmission under drug coverage, tests of the viability of
gametocytes for gamete activation using the MGFA with artemisinin derivatives; DHA,
artemether, and artemisone clearly found that certain PfK13C580Y and PfK13R539T par-
asites demonstrated significantly higher resistance compared to NF54. Of note, while
undertaking this work, a parallel study made similar observations. Testing male exflag-
ellation sensitivity to DHA in unrelated culture-adapted PfK13var Cambodian field
isolates, Lozano et al. found that PfK13var isolates showed a reduced sensitivity of
exflagellation rates to DHA treatment, though onward mosquito infectivity was not
tested (48). Extending this observation to transmission directly, we took the most
competent transmissible field isolate representing the resistant phenotype (APL5G,
PfK13C580Y) compared to the laboratory reference strain NF54, and tested whether
transmission resistance plays out in terms of capacity to infect mosquitoes over a range
of drug concentrations. Controlling for number of RBCs and hematocrit level for each,
infection prevalence in mosquitoes could then be tested and compared between drug
treatment of the same parasite isolate. Of note, the oocyst intensity (number of oocysts
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found in each mosquito) was consistently different between NF54 and APL5G, as it is
for each different culture-adapted parasite strain (40). These differences make direct
measures of mixed infections challenging. Nonetheless, we found that under DHA
pressure, transmission of the artemisinin resistant, PfK13C580Y (APL5G) was consistently
less impaired than transmission of NF54 (Figure 4c). This is due to the greater impact
of DHA on NF54 oocyst infection, which served to offset the decreased transmission
potential for APL5G in the absence of DHA. Our findings demonstrate that the
artemisinin-resistant phenotype of APL5G is not confined to asexual blood stages but,
additionally, expands to male sexual stages and directly influences transmission in the
presence of DHA. APL5G additionally carries a pfmdr1 amplification which has been
previously linked to asexual artemisinin resistance (44, 45). Yet, in a clinical setting, the
most prominent multidrug-resistant P. falciparum lineages show very low pfmdr1
amplification prevalence across the GMS (10, 49). Despite pfmdr1 copy number varia-
tions potentially having an association with increased DHA resistance during gamete
formation of APL5G, clinical evidence suggests this amplification is unlikely to have
provided a true advantage for wider transmission and manifestation outside the use of
the artemisinin partner drug mefloquine (10, 49).
Although the numbers are small here, the implications are that in the context of a
mixed infection, a resistant parasite isolate may be more likely to survive ACT treatment
and, additionally, its gametocytes may be more likely to transmit to the mosquito. Thus,
ACT coverage in the field may be favoring, even driving, artemisinin-resistant parasite
persistence and transmission. This could explain an important part of the selection of
PfK13 propeller mutants observed in the field. For instance, the F446I PfK13 mutation
results in only a slight prolongation in parasite clearance half-life and is not associated
with ACT treatment failure (16). Yet, there is clear selection of this genotype in Myanmar
and Southern China (50), which could be explained by preferential transmission under
artemisinin drug pressure. The effect on outcrossing is also worth considering. Because
the sterilizing effects of artemisinin-based drugs only affect the male gametocyte (21,
22), there is the very real potential that ACT usage in the context of a mixed infection
might favor acquisition of other selectively advantageous mutations during transmis-
sion. Since the female gametocytes remain unaffected, successful transmission under
ACT coverage would likely favor either resistant parasite selfing or mating between
resistant males and sensitive females. It is clear from our own usage of a central Asian
mosquito vector (A. stephensi) and the work of others using the major African vector,
A. coluzzii (40), that artemisinin-resistant parasites can infect nonnative mosquitoes.
Thus, in a mixed infection where local parasites show a degree of geographical vector
adaptation (51), an invasive resistant parasite, otherwise at a disadvantage (reduced
vector adaptation and slower asexual growth), may acquire a key advantage under ACT
coverage in terms of its ability to both transmit and acquire necessary adaptive
mutations via recombination with sensitive females. Importantly, this may play out
even without a decline in cure rates if transmissibility of the treated infection is
increased, such as in high-intensity transmission areas at the early stages of resistance
invasion before partner drug resistance has emerged. Mixed infection studies in vivo
and modeling of drug coverage effects with different rates of transmission intensity are
clearly needed to explore the implications of transmission resistance in various invasive
settings.
Ultimately, these data stress the importance of considering transmission in the
context of drug resistance spread and argue strongly for the inclusion of a parasite
transmission-blocking component in future antimalarial combination therapies or con-
trol strategies.
MATERIALS AND METHODS
P. falciparum asexual blood stage and gametocyte maintenance. Asexual blood stage and
gametocytes were cultured as previously described (38) with the following modifications. Asexual
blood-stage cultures were maintained in asexual culture medium (RPMI 1640 with 25 mM HEPES [Life
Technologies], 50 g liter1 hypoxanthine [Sigma], 5% A human serum [Interstate Blood-Bank], and
0.5% AlbuMAX II [Life Technologies]). Gametocyte cultures were maintained in gametocyte culture
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medium (RPMI 1640 with 25 mM HEPES [Life Technologies], 50 g liter1 hypoxanthine [Sigma], 2 g
liter1 sodium bicarbonate [Sigma], 5% A human serum [Interstate Blood-Bank], and 0.5% AlbuMAX II
[Life Technologies]).
Field isolates. All parasite isolates were sequenced and assessed for multiplicity of infection at
point-of-care baseline before ACT treatment. Selected isolates were sufficiently homozygous (based on
the value FWS delineated in reference 23), which allowed us to proceed without additional parasite
cloning steps. Interestingly, all copy number variations for APS3G, APL5G (mdr1), and APL4G (plasmepsin
II/III) were maintained after prolonged culture cultivation and several cryopreservation steps, as the same
copy number variations were found at baseline (52) and during our most recent sequence analysis in
2019.
Mosquito rearing. Anopheles stephensi mosquitoes were reared under standard conditions (26°C to
28°C, 65% to 80% relative humidity, 12 h:12 h light/darkness photoperiod). Adults were maintained on
10% fructose.
Whole-genome sequencing. Genomic DNA isolation, whole-genome sequencing, and calling of
single-nucleotide variants were undertaken essentially as recently described (52). To determine gene
amplification copy number variants, sashimi plots were created and visualized using the integrated
genomics viewer (IGV) (53) comparing aligned bam files. Sashimi plots were visually inspected for
increased read coverage over genes of interest.
Flow cytometry. To prepare parasites for the growth assay, asexual parasites were sorbitol-
synchronized at least twice 16 h apart to create an 8 h growth window. Briefly, cultures containing mainly
ring-stage parasites were incubated with 5% sorbitol at 37°C for 5 min, spun down, and resuspended in
culture medium. The second synchronization step was repeated 16 h later, resulting in a culture where
parasites were between 16 h to 24 h ring stages. To start the growth assay, parasitemia was seeded in
2 ml total volume at 2% hematocrit and 1 to 2% early ring stages in triplicates that were treated
separately. The assay was performed twice with 3 replicates each. Every 48 h and for a total of 8 days,
parasitemia was determined using flow cytometry and each well was diluted back to 1 to 2% parasitemia
as follows. One milliliter of each culture was fixed in 4% formaldehyde and 0.2% glutaraldehyde for at
least 10 min. After washing with phosphate-buffered saline (PBS), DNA was stained with SYBR green I
(diluted 1:10,000) in the dark for 20 min at room temperature. After incubation, cells were washed three
times with PBS and resuspended in 80 l PBS. Flow cytometry was performed counting a total of 100,000
cells per well. Cumulative growth was calculated based on absolute parasitemia and dilution factor for
each day.
Nuclei count. Parasites were synchronized twice using 5% sorbitol to obtain a 10-h life cycle window.
An aliquot of 10 M compound 2 was added to late trophozoite stages for a maximum of 12 h to block
egress of the RBCs (37). Resulting segmented schizonts were thinly smeared, then fixed with 4%
formaldehyde and 0.2% glutaraldehyde for 20 min. Smears were then stained with 1 g ml1 DAPI for
5 min and mounted in Vectashield (Vector Laboratories). Z-stacks were taken using a Leica microscope
at 100 magnification. Nuclei of arrested segmented schizonts were counted using the plugin tool
“Manual counting” on ICY (54). Only singly invaded RBC were counted.
Trophozoite maturation inhibition assay. The trophozoite maturation inhibition assay (TMI) was
performed as described (24). Briefly, P. falciparum-infected blood was collected into heparin-coated
vacutainer tubes and centrifuged at 800  g at 4°C for 5 min to allow the removal of the plasma and
buffy coat. This was followed by three washes in RPMI 1640 (without serum supplement) and adjusted
to 3% cell suspension in 10% A human serum-supplemented RPMI 1640. Then, 96-well microtiter plates
(Nunc MicroWell 96-well microplate; Thermo Fisher Scientific) were predosed with artesunate dissolved
in 5% NaHCO3 (Guilin Pharmaceutical Co., Ltd., China), ranging from 0.01 to 400 ng ml1 final concen-
tration or no drug as negative control. A 75-l P. falciparum ring stage infected RBC cell suspension was
added to the test plate and incubated for 24 h at 37°C in 5% CO2. All samples were tested in triplicate.
Upon completion of drug exposure, thick and thin blood smears were prepared of all wells and the
number of 24- to 30-h trophozoites (55) was counted per 100 infected RBCs. To identify the inhibition
activity of artesunate, the percentage of trophozoite maturation compared to the negative control was
assessed. The IC50 (50% inhibitory concentration) was calculated as the drug concentration causing 50%
inhibition of P. falciparum maturation from ring stage to trophozoite stage and normalized to the
negative-control wells. All IC50s were determined by sigmoid curve fitting using WinNonlin computer
software (version 3.1; Pharsight Corporation, USA). As a technical control, all ex vivo assays were
performed in parallel to the standard laboratory Thai strain TM267, which is a non-gametocyte-
producing line.
Male gamete formation assay double-dose format. The double dose male gamete formation assay
(MGFA) was adapted from previously described methods (22) to incorporate an additional drug dosage,
accounting for the low compound half-lives of artemisinin and its derivatives. Briefly, compounds were
prepared in 10 mM DMSO stocks and dispensed in serial dilutions into multiwell plates using an HP D300
digital dispenser. All drugs were supplied by the Medicines for Malaria Venture (MMV), including UCT048
(MMV048), NITD609 (Cipargamin), gentian violet, methylene blue, and DHA. Samples were normalized to
0.25% DMSO and contained 0.25% DMSO and 12.5 M gentian violet as negative and positive controls,
respectively. Half the maximal DMSO content was plated per plate, accounting for the accumulation of
DMSO over two dosages. Mature gametocytes with an exflagellation rate of 0.2% of total cells were
diluted in gametocyte culture medium to 25 million RBCs ml1. Mature gametocyte culture was plated
in drugged 96-well plates and incubated in a humidified chamber under 92% N2/5% CO2/3% O2 (BOC
special gases) at 37°C for 24 h. For the second drug dosage at 24 h, the drugged culture was transferred
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to a second drugged well plate and incubated for a further 24 h under 92% N2/5% CO2/3% O2 at 37°C
in a humidified chamber.
At 48 h, gametogenesis was induced with ookinete medium (RPMI 1640 with 25 mM HEPES [Life
Technologies], 50 g liter1 hypoxanthine [Sigma], 2 g liter1 sodium bicarbonate [Sigma], and 100 M
xanthurenic acid). Plates were immediately incubated at 4°C for 4 min and then 28°C for 5 min before
transferring to a Nikon Ti-E widefield microscope. Exflagellation events were recorded by automated
phase-contrast microscopy, in 96-well plates. Twenty-frame time lapses were recorded at 10 magni-
fication and 1.5 zoom. Exflagellation events per field were derived using an automated ICY Bioimage
Analysis algorithm. Resulting counts were converted to percentage inhibition values, calculated relative
to positive (C1) and negative (C2) controls:
%Inhibition  100   test compound  C1C2  C1   100 (1)
Raw data demonstrated a Z-score  0.4 and was derived from n  2 and n  3 technical and
biological replicates, respectively. GraphPad Prism (version 8) was used to calculate IC50s from the dose
response data using with the log(inhibitor) versus response–variable slope (four parameters) function.
IC50s were derived from curves demonstrating R2  0.95.
In vitro simulated DHA half-life and wash-out assays. P. falciparum NF54 gametocyte cultures
were seeded according to the MGFA protocol on the same day from the same inoculum and maintained
in Nunc EasYFlask cell culture flasks (Thermo Fisher Scientific, Nunclon Delta surface treated, 25 cm2).
DHA was kindly provided by Medicines for Malaria Venture and prepared at a 10 mM stock solution in
DMSO and stored at 20°C until further use.
On the day of the half-life assay, nonpurified stage III (culture day 9) and stage V (culture day 14)
gametocyte cultures were assessed for their gametocytaemia with Giemsa smears and stage V also
checked for male gametocyte exflagellation. Each culture was split into two Nunc EasYFlask cell culture
flasks (25 cm2), exposed to 92% N2/5% CO2/3% O2, and cells were allowed to settle for 1 h at 37°C. Culture
supernatants were removed and replaced with freshly prepared and prewarmed 10 ml gametocyte
culture RPMI containing 0.25% DMSO or 3.5 M DHA (0.25% DMSO final), exposed to 92% N2/5% CO2/3%
O2, and cells were allowed to settle at 37°C. After 50 min, culture supernatants were aspirated and
replaced with 10 ml of freshly prepared and prewarmed gametocyte culture RPMI containing DMSO in
the control culture or 1.75 M DHA for the treatment culture (half of the initial DHA concentration). This
step was repeated until a final exposure of 0.027 M DHA was reached (8 exposure steps). Culture
supernatants were then replaced with 10 ml of prewarmed gametocyte culture RPMI and incubated for
2 h before replacement of supernatants with fresh gametocyte culture RPMI. This washing step was
repeated 3 times in total. Gametocyte cultures were then matured until day 15 (stage III) and day 16
(stage V) culture. Exflagellation was assessed according to the MGFA and inhibitions quantified to DMSO
controls.
For single-dose DHA wash-out assays, nonpurified stage III, IV, and V (culture days 9, 11, and 14,
respectively) gametocytes were each split into two Nunc EasYFlask cell culture flasks (25 cm2) and
incubated with 10 ml of freshly prepared and prewarmed gametocyte culture RPMI containing either
0.25% DMSO or 1.6 M DHA, exposed to 92% N2/5% CO2/3% O2, and kept at 37°C for 24 h. Supernatants
were aspirated and all cultures were washed 3 times for 2 h each time, according to the half-life washing
steps above. Gametocytes were then further cultured until day 14 (stage III and stage IV) and day 15
(stage V). Exflagellation levels were measured according to the MGFA. Gametocytaemia was counted per
1,000 RBC.
Standard membrane feeding assay. Gametocytes were induced and maintained as described
above. At day 14 postinduction, gametocytes were spun down at 38°C and resuspended in 5 ml of
suspended animation buffer (SA) (56). To ensure that a consistent number of RBCs and gametocytaemia
were used for drug incubation for each isolate, gametocytes were magnetically activated cell sorting
(MACS)-purified and resuspended in gametocyte medium with 25  106 fresh RBCs. DHA or DMSO was
added to the desired end concentration into a 10-ml gametocyte culture and added again 24 h later
(double-dosing within 48 h). After 48 h, the parasite culture was mixed with fresh blood and human
serum and fed to adult A. stephensi mosquitoes using a 3D-printed feeder (39).
Oocyst counts and size. At day 10 postfeeding, mosquitoes were dissected, midguts were stained
in 0.1% mercurochrome, and then inspected using light microscopy with 10 magnification to count
oocysts.
To measure oocyst size, midguts of A. stephensi fed on P. falciparum-infected blood were dissected
and fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100 for 1 h, blocked with 3% bovine
serum albumin (BSA) for 30 min, and stained with 1 g ml1 in DAPI for 3 min. Midguts were washed
with 1 PBS and mounted in Vectashield. Images were acquired on a Nikon Ti-Eclipse inverted
fluorescence microscope. Images of P. falciparum-infected midguts were captured using the DAPI
channel and z-stack imaging to obtain greater depth of oocysts. These stacked images were then
processed in ND Processing using the Maximum Intensity Projection option, which then created an
image with brighter intensity of the oocysts in every midgut. Oocyst detection was automated by using
the Automated Spot Detection program based on the intensity of the oocysts compared to midgut cells
(NIS-Elements). The size, diameter, and intensity of each selected oocyst were recorded in an MS Excel
file for analysis.
Statistical modeling of oocyst infection intensity and prevalence. To assess the impact of
artemisinin on the ability of each parasite line to form oocysts, we used generalized linear mixed effects
models to incorporate data from different experimental replicates within the same modeling framework.
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These models have previously been used to model transmission-blocking interventions (57). We modeled
either infection intensity or prevalence as the response with treatment (DHA concentration) included as
a fixed effect and 0 M DHA represented by control groups treated with DMSO. The parasite line that was
treated (PfK13WT or PfK13C580Y) was included as a fixed effect to assess the differential impact of
artemisinin on transmission success. The impact of treatment between experimental replicates was
allowed to vary at random between replicates. A logistic regression (binomial error structure) was used
to model the prevalence of mosquito infection, i.e., the presence or absence of oocysts, and a
zero-inflated negative binomial distribution was used to model the intensity of infections, i.e., the
numbers of mosquito oocysts (58). The 95% confidence interval estimates were generated for the impact
of drug concentration by bootstrapping methodology (with 100,000 replicates).
Data availability. Raw experimental data are available on request, while genomic data are publicly
available at the European Nucleotide Archive (https://www.ebi.ac.uk/ena). Accession numbers, group
ERP121586 and individual: ARN1G (ERS3395814); APS2G (ERS3395811); APS3G (ERS3395812); APL4G
(ERS3395813); and APL5G (ERS3395810). The NF54 reference genome is available through https://
plasmodb.org/plasmo/.
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